• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Mind Medicine (MindMed) Inc.

    11/14/24 4:05:16 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MNMD alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Mind Medicine (MindMed) Inc.

     

    (Name of Issuer)

     

    Common Shares, no par value per share

     

    (Title of Class of Securities)

     

    60255C885

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    8,176,721*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    8,176,721*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,176,721*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12

    TYPE OF REPORTING PERSON

     

    IA

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    8,176,721*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    8,176,721*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,176,721*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12

    TYPE OF REPORTING PERSON

     

    OO

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    Item 1. (a) Name of Issuer

     

    Mind Medicine (MindMed) Inc. (the “Issuer”)

     

    Item 1. (b) Address of Issuer’s Principal Executive Offices

     

    One World Trade Center, Suite 8500, New York, New York 10007

     

    Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:
       
      This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.

     

    Item 2. (d) Title of Class of Securities

     

    Common Shares, no par value per share (the “Common Shares”)

     

    Item 2. (e) CUSIP No.:

     

    60255C885

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

     

    N/A

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    Item 4. Ownership

     

    As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:

     

    (a) Amount Beneficially Owned: 8,176,721*

     

    (b) Percent of Class: 9.9%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 8,176,721*

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 8,176,721*

     

    As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:

     

    (a) Amount Beneficially Owned: 8,176,721*

     

    (b) Percent of Class: 9.9%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 8,176,721*

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 8,176,721*

     

    *The Firm is the investment manager to Commodore Master. As of September 30, 2024, the Firm may be deemed to beneficially own an aggregate of 8,176,721 Common Shares of the Issuer, consisting of (i) 8,000,000 Common Shares and (ii) 176,721 Common Shares underlying a warrant, which is subject to a beneficial ownership limitation of 9.99%. The foregoing excludes 1,252,054 Common Shares underlying a warrant, which is subject to a beneficial ownership limitation of 9.99%. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 81,590,491 Common Shares reported as issued and outstanding as of September 30, 2024 in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibit Index

     

    1. Joint Filing Agreement dated as of March 21, 2024, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on March 21, 2024).

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: November 14, 2024
       
      Commodore Capital LP
         
      By: /s/ Michael Kramarz
      Michael Kramarz, Managing Partner
         
      Commodore Capital Master LP
         
      By: /s/ Michael Kramarz
      Michael Kramarz, Authorized Signatory

     

     

     

    Get the next $MNMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNMD

    DatePrice TargetRatingAnalyst
    1/28/2025$23.00Outperform
    Evercore ISI
    12/20/2024$20.00Buy
    Chardan Capital Markets
    10/14/2024$20.00Outperform
    Leerink Partners
    7/24/2024$36.00Buy
    ROTH MKM
    5/29/2024$27.00Outperform
    Robert W. Baird
    4/15/2024$20.00Outperform
    Leerink Partners
    12/5/2023$9.00Buy
    Canaccord Genuity
    12/9/2022$25.00Buy
    ROTH Capital
    More analyst ratings

    $MNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will present at the 2025 RBC Capital Markets Global Healthcare Conference: 2025 RBC Capital Markets Global Healthcare Conference Format: Fireside Chat and 1x1 Meetings Date: May 21, 2025, at 2:05 PM ET Location: New York, NY Webcast Link: 2025 RBC Capital Markets Global Healthcare Conference Audio webcasts and replays of available presentations will be accessible on MindMed's Investor Relations website for up to 90 days following

      5/13/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

      --Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026-- --Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its first quarter 2025 financial results and pro

      5/8/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webca

      4/24/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Karlin Daniel sold $46,075 worth of shares (6,836 units at $6.74), decreasing direct ownership by 2% to 446,177 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      3/26/25 5:00:17 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Barrow Robert sold $142,942 worth of shares (21,208 units at $6.74), decreasing direct ownership by 2% to 856,556 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      3/26/25 5:00:18 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Legal Officer Sullivan Mark sold $44,322 worth of shares (6,576 units at $6.74), decreasing direct ownership by 2% to 316,621 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      3/26/25 5:00:13 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gryska David W bought $17,925 worth of shares (2,500 units at $7.17), increasing direct ownership by 14% to 19,851 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      12/5/24 4:30:05 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Gryska David W bought $20,930 worth of shares (3,500 units at $5.98), increasing direct ownership by 25% to 17,351 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/26/24 7:00:03 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Barrow Robert bought $6,215 worth of shares (1,000 units at $6.21), increasing direct ownership by 0.18% to 565,543 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/20/24 9:14:04 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Financials

    Live finance-specific insights

    See more

    $MNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

      --Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026-- --Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its first quarter 2025 financial results and pro

      5/8/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webca

      4/24/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

      --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder (MDD) in 1H of 2025-- --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 8:00

      3/6/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mind Medicine (MindMed) Inc.

      SC 13G/A - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      11/14/24 4:05:16 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

      SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      3/21/24 4:05:38 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

      SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      3/15/24 4:08:37 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on MindMed with a new price target

      Evercore ISI initiated coverage of MindMed with a rating of Outperform and set a new price target of $23.00

      1/28/25 7:14:33 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chardan Capital Markets initiated coverage on MindMed with a new price target

      Chardan Capital Markets initiated coverage of MindMed with a rating of Buy and set a new price target of $20.00

      12/20/24 7:44:37 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Leerink Partners resumed coverage on MindMed with a new price target

      Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00

      10/14/24 7:36:33 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Leadership Updates

    Live Leadership Updates

    See more
    • MindMed Appoints Matt Wiley as Chief Commercial Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company's commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317

      3/17/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,

      12/3/24 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o

      11/18/24 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.

      10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/8/25 7:25:20 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/8/25 7:15:09 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form D filed by Mind Medicine (MindMed) Inc.

      D - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/5/25 4:06:27 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care